Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...

Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability. Catalyst Pharmaceutical Partners NewsMORE Related Stocks ...

The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or ...

Source: Catalyst Pharmaceuticals, Inc. Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Catalyst Pharmaceutical Partners NewsMORE Related Stocks ...

Ken Chenault and Ken Frazier said it would be harder to get CEOs to take a stand on issues like voting rights today than in ...

Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 15 shareholders ...

(NASDAQ: CPRX) for North America, focusing on commercialization of AGAMREE in DMD and exploring joint development of indications beyond DMD First launches – first launch in Germany, followed by U.S.

Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact: David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com ...

Source: Catalyst Pharmaceuticals, Inc. Investor Relations Contact: Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact: David Schull, Russo Partners ...

Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact: David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com ...